Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Intercept Pharmaceut (ICPT) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,872,880
  • Shares Outstanding, K 24,730
  • Annual Sales, $ 2,780 K
  • Annual Income, $ -226,430 K
  • 36-Month Beta -2.12
  • Price/Sales 247.66
  • Price/Book 6.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
101.96 +8.02%
on 12/22/16
117.72 -6.44%
on 12/28/16
+1.00 (+0.92%)
since 12/20/16
3-Month
96.63 +13.98%
on 11/04/16
139.44 -21.01%
on 10/24/16
-27.71 (-20.10%)
since 10/20/16
52-Week
89.76 +22.70%
on 02/11/16
177.93 -38.10%
on 08/01/16
-9.97 (-8.30%)
since 01/20/16

Most Recent Stories

More News
Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug

Shares of Alcobra Ltd. (ADHD) declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on ADHD drug, metadoxine, extended release.

Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?

Shares of Merrimack Pharmaceuticals Inc (MACK) have increased 47.9% in the last twelve months as the company looks to restructure business.

Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3%

Intercept Pharmaceuticals, Inc. (ICPT) shares rose over 9% in the last trading session.

Intercept (ICPT) Ocaliva Gains Conditional Approval in EU

Intercept (ICPT) Ocaliva, in combination with UDCA, was approved in the EU for the treatment of PBC.

Blog Coverage Intercept Pharma Receives European Approval for the Treatment of a Rare Liver Condition

Upcoming AWS Coverage on Ascendis Pharma Post-Earnings Results

European Commission Grants Intercept's Ocaliva(R) (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

NEW YORK, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...

European Commission Grants Intercept's Ocaliva(R) (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases,...

Intercept to Present at Upcoming Investor Conference

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

Amazon.com trade offers a 6.05% return in 74 days, or find similar option trades on Intercept Pharmaceuticals, Energous Corporation, Opko Health, and 3D Systems

InvestorsObserver issues critical PriceWatch Alerts for AMZN, DDD, ICPT, OPK, and WATT.

Intercept Presents New Data at AASLD Examining the Effects of Ocaliva(R) (Obeticholic Acid) on Non-Invasive Assessments of Liver Fibrosis in Patients with PBC

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases,...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Support & Resistance

2nd Resistance Point 116.09
1st Resistance Point 113.11
Last Price 110.14
1st Support Level 107.89
2nd Support Level 105.65

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.